Societal value of lecanemab in Japan published in Neurology and Therapy

Stockholm, May 17, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of results from a simulation study evaluating the societal value of lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta…

Leave a Reply

Your email address will not be published. Required fields are marked *